Completed × Squamous Cell Carcinoma of Head and Neck × Thoracic × Clear all Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Phase 2 Completed
161 enrolled
Priming Immunotherapy in Advanced Disease With Radiation
Phase 2 Completed
76 enrolled 9 charts
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Completed
135 enrolled
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
40 enrolled
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Phase 1 Completed
6 enrolled
Study of DF9001 in Patients With Advanced Solid Tumors
Phase 1/2 Completed
24 enrolled
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
Phase 2 Completed
42 enrolled 40 charts
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
Phase 1/2 Completed
114 enrolled
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use
Phase NA Completed
19 enrolled
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Phase 1 Completed
17 enrolled
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
Completed
130 enrolled
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Phase 1 Completed
41 enrolled
ABIMMUNE
Phase 1/2 Completed
54 enrolled
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Phase 1 Completed
112 enrolled
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Phase 1 Completed
67 enrolled
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Phase 1 Completed
64 enrolled
ACTolog
Phase 1 Completed
38 enrolled
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
Phase 1/2 Completed
323 enrolled
CLOVER
Phase 1 Completed
105 enrolled
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
38 enrolled
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Phase 1 Completed
48 enrolled
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Phase 1/2 Completed
126 enrolled
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Phase 1/2 Completed
12 enrolled
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Phase 1/2 Completed
26 enrolled 47 charts
DUET-3
Phase 1 Completed
198 enrolled
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Phase 1 Completed
22 enrolled
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Phase 1 Completed
29 enrolled
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Phase 1 Completed
35 enrolled
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
Phase 1 Completed
78 enrolled
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Phase 1 Completed
14 enrolled 13 charts
A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China
Completed
3,102 enrolled
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
Phase 1 Completed
16 enrolled
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Phase 1 Completed
11 enrolled
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Phase 1 Completed
19 enrolled
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
Phase 2 Completed
30 enrolled 20 charts
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1 Completed
38 enrolled
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Phase NA Completed
434 enrolled
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Phase 1 Completed
36 enrolled
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
Phase 1 Completed
12 enrolled
DUET-4
Phase 1 Completed
78 enrolled
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Phase 1 Completed
13 enrolled 10 charts
DUET-2
Phase 1 Completed
150 enrolled